NCT06422572Completed
Tissue Kallikrein Protect Against Ischemic Stroke
The Role of Tissue Kallikrein - Bradykinin System Targeting the Protection of Neurovascular Units in Ischemic Areas of Stroke
Source: ClinicalTrials.gov · Last updated 21 May 2024
Brief summary (registry, in English)
The results of previous studies were used to assess the causal association between TK levels and stroke occurrence at 5 and 12 years of follow-up, respectively.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 8602 (actual)
- First submitted
- 7 May 2024
- Start date
- 1 May 2023
- Primary completion date
- 30 Dec 2023
- Lead sponsor
- Qin Zhang
- Diseases
- Stroke
- NCT number
- NCT06422572
What you commit to
- Study type: Observational
- Participants enrolled: 8602
- From 1 May 2023 to the primary completion date, 30 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Stroke patient
Who the study is looking for
- 1\) Control population in the previous stroke case-control study;
- 2\) The CHD case-control population in the previous study;
- 3\) The population in the community cross-sectional study of the previous study.
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.